Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | ADH1B | P00325 | 2/20 | 0.46 |
| ▸ | ADH1A | P07327 | 2/20 | 0.46 |
| ▸ | ADH7 | P40394 | 2/20 | 0.46 |
| ▸ | ADH1C | P00326 | 1/20 | 0.46 |
| ▸ | ADH4 | P08319 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11508516 | 1.00 | TSHR (0.69) | TSHRALDH1A1PAOXCYP2C19CYP1A2 | |
| SCHEMBL4211605 | 1.00 | TSHR (0.69) | TSHRALDH1A1PAOXCYP2C19CYP1A2 | |
| SCHEMBL7512916 | 1.00 | TSHR (0.69) | TSHRALDH1A1PAOXCYP2C19CYP1A2 | |
| SCHEMBL1248078 | 1.00 | TSHR (0.69) | TSHRALDH1A1PAOXCYP2C19CYP1A2 | |
| SCHEMBL11508173 | 1.00 | TSHR (0.69) | TSHRALDH1A1PAOXCYP2C19CYP1A2 | |
| SCHEMBL2639821 | 0.97 | TSHR (0.65) | TSHRALDH1A1PAOXCYP2C19CYP1A2 | |
| Bromide SCHEMBL7596439 | 0.97 | TSHR (0.65) | TSHRALDH1A1PAOXCYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL7512068 | 0.97 | TSHR (0.65) | TSHRALDH1A1PAOXCYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL7512398 | 0.97 | TSHR (0.65) | TSHRALDH1A1PAOXCYP2C19CYP1A2 | |
| Bromide SCHEMBL7601203 | 0.97 | TSHR (0.65) | TSHRALDH1A1PAOXCYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022216754-A1 | THERMAL INTERFACE MATERIALS BY POLYMERIZATION INDUCED PHASE SEPARATION | ADAPTIVE 3D TECHNOLOGIES, LLC (US) | 2022-10-13 | — | — | WO | disclosed |
| US-11147833-B2 | Therapeutic agent for hyperphosphatemia | FUJIFILM CORPORATION (JP) | 2021-10-19 | — | — | US | disclosed |
| US-20190321392-A1 | THERAPEUTIC AGENT FOR HYPERPHOSPHATEMIA | FUJIFILM CORPORATION (JP) | 2019-10-24 | — | — | US | disclosed |
| EP-1828354-B1 | HYDROCARBYL SUCCINIC ACID AND HYDROCARBYLSUCCINIC ACID DERIVATIVES AS FRICTION MODIFIERS | BASF SE (DE) | 2017-09-06 | — | — | EP | disclosed |
| US-20110117164-A1 | Use of Additive Sites to Control Nitric Oxide Release from Nitric Oxide Donors Contained within Polymers | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2011-05-19 | — | — | US | disclosed |
| WO-2009135877-A1 | DIBLOCK COPOLYMER-SUBSTITUTED SUCCINIC ACID DERIVATIVES | BASF SE (DE) | 2009-11-12 | — | — | WO | disclosed |
| EP-1828354-A1 | HYDROCARBYL SUCCINIC ACID AND HYDROCARBYLSUCCINIC ACID DERIVATIVES AS FRICTION MODIFIERS | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063770-A1 | HYDROCARBYL SUCCINIC ACID AND HYDROCARBYLSUCCINIC ACID DERIVATIVES AS FRICTION MODIFIERS | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-22 | — | — | WO | disclosed |
| EP-1669433-A1 | Hydrocarbyl succinic acid and hydrocarbylsuccinic acid derivatives as friction modifiers | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-14 | — | — | EP | disclosed |
| US-20060008529-A1 | Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-01-12 | — | — | US | disclosed |
| EP-0001797-B1 | PROCESS FOR THE ISOLATION OF CEPHALOSPORIN C, ITS SALTS AND ITS DERIVATIVES, FROM CULTURE MEDIA AND SOLUTIONS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-06-17 | — | — | EP | disclosed |
| US-4204058-A | Process for obtaining cephalosporin C and the salts and derivatives thereof from culture filtrates or culture solutions | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-05-20 | — | — | US | disclosed |
| EP-0001797-A1 | Process for the isolation of cephalosporin C, its salts and its derivatives, from culture media and solutions | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-05-16 | — | — | EP | disclosed |
| US-4140860-A | BACTERICIDES | STERLING DRUG INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4119668-A | ANTIBACTERIAL AGENTS | STERLING DRUG INC. (US) | 1978-10-10 | — | — | US | disclosed |
| US-4085144-A | ANTIBACTERIAL | STERLING DRUG INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4022833-A | ANTIBACTERIAL AGENTS | STERLING DRUG INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117164-A1 | Use of Additive Sites to Control Nitric Oxide Release from Nitric Oxide Donors Contained within Polymers | NOS1, NOS2, NOS3 | TSHR 4279/4885ALDH1A1 1430/4885PAOX 1273/4885 |
| US-20190321392-A1 | THERAPEUTIC AGENT FOR HYPERPHOSPHATEMIA | PHPT1, PPIP5K2, PTH1R | TSHR 3230/4885ALDH1A1 3982/4885PAOX 1561/4885 |
| US-20060008529-A1 | Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers | NOS1, NOS2, NOS3 | TSHR 4279/4885ALDH1A1 1430/4885PAOX 1273/4885 |
| US-11147833-B2 | Therapeutic agent for hyperphosphatemia | PHPT1, PPIP5K2, PTH1R | TSHR 3230/4885ALDH1A1 3982/4885PAOX 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.